Current evidence answer
Posted phase 2 results record constipation by study group
ClinicalTrials.gov posts adverse-event results for the completed phase 2 obesity study. Constipation was systematically assessed over baseline through safety follow-up and appears under a reporting threshold of at least 5% in any treatment group. The table records 2 of 70 participants in the placebo group and, across six separate retatrutide groups, counts ranging from 2 of 69 to 10 of 62. These are group-specific research counts, not an approved patient incidence or a prediction for one person.
- Do not add the groups together casually, omit placebo, or turn the highest group count into the expected risk for every future patient.
- The peer-reviewed phase 2 report describes gastrointestinal events overall as dose-related and mostly mild to moderate; it does not establish a constipation timeline or treatment recipe.
- A monitored trial product does not verify the identity, concentration, sterility, storage, or handling of a vial sold online as “Reta.”
Phase 3 context
TRIUMPH-1 completion is a pipeline signal, not a constipation label
ClinicalTrials.gov lists TRIUMPH-1, a phase 3 retatrutide study in adults with obesity or overweight, as completed on April 30, 2026 and last updated on June 3, 2026. The registry currently shows no posted results. Trial completion can increase search interest, but patients still need a public FDA decision and approved prescribing information before routine indications, contraindications, warnings, dosing, packaging, constipation rates, and pharmacy access can be treated as established.
- Retatrutide remains investigational even after a phase 3 study reaches its completion date.
- Future peer-reviewed reports or FDA labeling may change the evidence on gastrointestinal events, severity, timing, discontinuations, and monitoring.
- A trial listing, sponsor headline, research-use label, or seller certificate of analysis is not a prescription or legitimate retail access pathway.
Symptom pattern and urgency
Constipation and obstruction-like symptoms need different responses
MedlinePlus describes constipation as fewer than three bowel movements a week, with stool that may be hard, dry, or painful to pass, but an individual change from the usual bowel pattern also matters. NIDDK advises immediate medical assessment when constipation occurs with rectal bleeding or blood in stool, constant abdominal pain, inability to pass gas, vomiting, fever, lower-back pain, or unintentional weight loss. Marked swelling, fainting, confusion, severe weakness, or inability to keep fluids down also should not wait for seller chat or a routine online article.
- Record the last bowel movement, stool consistency, straining, ability to pass gas, abdominal swelling, pain location and severity, nausea or vomiting, fever, bleeding, intake, and urine output.
- Contact a clinician for a persistent, worsening, painful, recurrent, or activity-limiting change, especially with prior bowel disease, abdominal surgery, pregnancy, kidney or heart disease, or diabetes medicines.
- Use prompt in-person care rather than a home “clean-out” when bleeding, constant or severe pain, inability to pass gas, vomiting, fever, marked swelling, dehydration, or rapidly worsening illness is present.
Medication and cause review
Do not assume every bowel change is a retatrutide effect
Constipation may have more than one cause. Lower food or fluid intake, reduced activity, travel, illness, pregnancy, prior bowel or pelvic-floor conditions, and medicines or supplements can contribute. NIDDK lists examples that include some antacids, anticholinergic medicines, anticonvulsants, calcium-channel blockers, diuretics, iron, narcotic pain medicines, and some depression medicines. Timing after an unverified injection cannot establish either product identity or causation.
- Bring the complete prescription, over-the-counter medicine, vitamin, mineral, laxative, fiber, antacid, pain-medicine, antihistamine, supplement, alcohol, and cannabis list.
- Share prior bowel obstruction or surgery, hernia, severe gastroparesis, pelvic-floor problems, kidney or heart disease, pregnancy possibility, recent illness, and changes in food, fluid, activity, or weight.
- Do not combine laxatives, use repeated enemas, start a detox, or follow an online bowel-cleanout protocol without individualized clinician or pharmacist review.
No self-treatment protocol
An investigational symptom page should not become a dose or laxative recipe
Retatrutide has no approved consumer instruction for delaying, reducing, splitting, repeating, restarting, or stopping a retail dose because there is no approved retail product. Generic advice to add fiber, fluids, magnesium, a laxative, suppository, or enema can be unsafe when vomiting, severe pain, inability to pass gas, bowel obstruction, kidney or heart disease, pregnancy, fluid restrictions, or medication interactions are possible. Decisions belong with the responsible study team or the clinician managing an approved or legally appropriate current treatment.
- Do not use copied trial schedules, syringe-unit conversions, “microdosing” plans, reconstitution instructions, or influencer titration charts.
- Legitimate trial participants should report bowel changes through the study team and follow the protocol’s contact and escalation instructions.
- Anyone using another prescription should identify the exact medicine and contact its prescriber rather than treating retatrutide research as a substitute label.
Current care and seller safety
Retatrutide constipation searches should not lead to “Reta” checkout
Peptide12 does not list retatrutide in its current product catalog. People searching for retatrutide constipation may be following phase 3 news, comparing future treatments with current semaglutide or tirzepatide pathways, or experiencing symptoms after an unverified product. A licensed clinician can review approved or legally appropriate current options, bowel history, medications, prior GLP-1 tolerance, pharmacy sourcing, cost, and follow-up. Compounded preparations are not FDA-approved finished drug products, and a patient-specific compounded semaglutide or tirzepatide discussion does not make compounded retatrutide legitimate.
- Ask whether the product is an FDA-approved brand, a patient-specific compounded preparation, a legitimate clinical-trial product, or an unverified research chemical.
- Avoid “Reta” sold for human use through research-chemical stores, no-prescription checkout, hidden pharmacy channels, copied protocols, bulk powder, or guaranteed low-side-effect claims.
- For current care, verify prescriber identity, pharmacy identity, exact product and route, approved or compounded status, labeling, storage, follow-up, urgent contact instructions, and total cost.